Compare Abeona Therapeutics Inc (ABEO) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Wheaton Precious Metals Corp — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Wheaton Precious Metals Corp trades at $107.75 (market cap $50.76B). The key difference: Wheaton Precious Metals Corp is far larger — about 136× Abeona Therapeutics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.7% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WPM | |
|---|---|---|
Market Cap | $373.32M | $50.76B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $165.72 |
52-Week Low | $4.17 | $86.72 |
Enterprise Value | $228.22M | $48.61B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Wheaton Precious Metals (WPM) trades at $111.89, down 3.32% recently amid broader precious metals volatility. The stock shows strong fundamentals with record 2025 revenue of $2.31B and net income of $1.47B, supported by three consecutive quarterly EPS beats. Technical indicators signal bearish momentum with key support at $109, while analyst consensus remains strongly bullish with an $169 price target representing 51% upside potential from current levels.
WPM presents a compelling growth story with exceptional profitability margins (65.55% net income margin) and projected 2026 revenue growth to $2.7B. Primary risks include precious metal price volatility and geopolitical tensions affecting mining operations. The 80% buy rating from analysts suggests significant upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
